NGS-Based ctDNA Profiling After the Resistance of Second-Line Osimertinib for Patient with EGFR-Mutated Pulmonary Adenocarcinoma

• Main Authors: Li D, Yang D, Cui S, Pan E, Yang P, Dai Z
• Format: Article in Journal/Newspaper
• Language: English
• Published: Dove Medical Press 2021
• Subjects: osimertinib; acquired resistance; egfr mutation; lung adenocarcinoma; circulating tumor dna; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282; Evenki; Zhongshan
• Online Access: https://doaj.org/article/6e11f41a14054b62a534884fc7c805e8

Dan Li,1,* DaFu Yang,1,* SaiQiong Cui,1 Evenki Pan,2 Peng Yang,2 ZhaoXia Dai1 1The Second Department of Thoracic Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, Liaoning, People’s Republic of China; 2Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, People’s Republic of...